Mavroudis, D., Saloustros, E., Boukovinas, I., Papakotoulas, P., Kakolyris, S., Ziras, N., . . . Georgoulias, V. (2017). Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: An interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. Br J Cancer.
Dyfyniad Arddull ChicagoMavroudis, Dimitrios, et al. "Sequential Vs Concurrent Epirubicin and Docetaxel As Adjuvant Chemotherapy for High-risk, Node-negative, Early Breast Cancer: An Interim Analysis of a Randomised Phase III Study From the Hellenic Oncology Research Group." Br J Cancer 2017.
Dyfyniad MLAMavroudis, Dimitrios, et al. "Sequential Vs Concurrent Epirubicin and Docetaxel As Adjuvant Chemotherapy for High-risk, Node-negative, Early Breast Cancer: An Interim Analysis of a Randomised Phase III Study From the Hellenic Oncology Research Group." Br J Cancer 2017.